CVT Shareholders Sue To Stop $1.4B Biotech Merger

By Marius Meland · March 24, 2009, 12:00 AM EDT

Shareholders of CV Therapeutics have filed a proposed class action in a California state court to stop the company from carrying out a proposed $1.4 billion merger with Gilead Sciences, which...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login